Cancer Therapy News and Research

RSS

Lipid overload in ascites weakens immune response in ovarian cancer

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies.

13 May 2025

DiffInvex identifies key genes driving chemotherapy resistance

Just as species adapt over generations, our body's cells accumulate DNA changes throughout life. Most are harmless, yet a few "driver" mutations give a cell a competitive edge and can spark cancer.

13 May 2025

Exploring the role of RNA binding proteins and circular RNAs in cancer

The interaction between RNA-binding proteins (RBPs) and circular RNAs (circRNAs) has emerged as a key area of interest in understanding cancer biology.

12 May 2025

AI tool uses facial images to predict biological age and cancer survival

Eyes may be the window to the soul, but a person's biological age could be reflected in their facial characteristics. Investigators from Mass General Brigham developed a deep learning algorithm called FaceAge that uses a photo of a person's face to predict biological age and survival outcomes for patients with cancer.

8 May 2025

Dana-Farber experts present innovative cancer studies at the 2025 AACR Annual Meeting

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

27 Apr 2025

Novel cancer immunotherapy approach could complement existing CAR-T treatments

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

24 Apr 2025

Manipulating a master regulator prevents tumor growth in mice

A protein identified nearly 40 years ago for its ability to stimulate the production of red blood cells plays a surprising, critical role in dampening the immune system's response to cancer.

24 Apr 2025

The dual role of microRNAs in lung cancer progression and suppression

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

18 Apr 2025

New discovery enhances cell entry for complex cancer drugs

A new discovery could pave the way for more effective cancer treatment by helping certain drugs work better inside the body.

17 Apr 2025

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

CellVoyant leverages AI and live-cell imaging to predict cellular behavior, transforming cell therapy development and making it more accessible and efficient.

16 Apr 2025

UVA scientist secures funding to use sound waves for breast cancer therapy

University of Virginia researcher Natasha D. Sheybani, PhD, has received $5.5 million from the federal Department of Defense to support her cutting-edge efforts to use focused sound waves to improve our immune system's ability to battle breast cancer.

15 Apr 2025

Study overcomes chemotherapy limitations with lipid nanoparticles

Announcing a new article publication for the BIO Integration journal. Lipid-based Nanoparticles (LBNPs) have emerged as a transformative approach in cancer treatment, offering innovative drug delivery solutions that enhance therapeutic efficacy while minimizing adverse effects.

10 Apr 2025

UCLA study identifies key protein driving kidney scarring

New UCLA research conducted using mouse models and human genetic data has uncovered a critical factor that determines how much scarring occurs following kidney injury, leading scientists to identify a potential precision medicine approach to prevent chronic kidney disease progression.

9 Apr 2025

ETH Zurich researchers identify redundancies between the genes involved in DNA repair

Researchers aThe DNA of human cells consists of a sequence of about 3.1 billion building blocks. Cells go to great lengths to maintain the integrity of this vast store of information.t ETH Zurich have unraveled the complex network that cells use to repair their genetic material.

9 Apr 2025

OICR funds five innovative cancer drug discovery projects

The Ontario Institute for Cancer Research (OICR) has announced its support for five Ontario research teams working to develop the next generation of medicines that kill tumours more effectively, cause fewer side effects and reduce the risk that cancer will come back.

3 Apr 2025

Blood cancer patients should continue BTKi therapy during COVID-19 vaccination

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 vaccinations, a new study suggests.

2 Apr 2025

Novel insights into tumor microenvironment and gastric cancer therapy

A team of Singapore scientists has made a significant discovery in understanding stomach cancer, a disease that remains one of the deadliest cancers worldwide. By using advanced mapping technologies, they created a detailed "atlas" of stomach tumors, revealing hidden patterns in how cancer cells behave, evolve and interact with their environment. These insights could lead to more precise, targeted treatments that improve survival rates and reduce side effects.

27 Mar 2025

Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs).

26 Mar 2025

Uniquely-shaped magnetic nanoparticles offer breakthrough in cancer therapy

New magnetic nanoparticles in the shape of a cube sandwiched between two pyramids represent a breakthrough for treating ovarian tumors and possibly other types of cancer, according to the Oregon State University researchers who developed them.

19 Mar 2025

Targeted inhibition of a 'signal jammer' protein may improve tumor response to immunotherapy

Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, a new study demonstrates how some cancer cells use the protein voltage-dependent anion channel 2 (VDAC2) like a signal jammer to prevent the body's anticancer systems from communicating with the immune system.

19 Mar 2025